פרופ' גל מרקל

מיקרוביולוגיה ואימונולוגיה קלינית סגל אקדמי קליני
פרופ' גל מרקל
טלפון חיצוני: 03-5304591
פקס: 03-5304922

קורות חיים

 

2008 -2005     חוקר עצמאי במכון אלה למלנומה, שיבא

 

2008-2010      מרצה, מיקרוביולוגיה ואימונולוגיה קלינית, סאקלר, אוניברסיטת תל אביב

 

2008 - היום     מדען ראשי, מכון אלה למלנומה, שיבא

 

2010 - היום     מרצה בכיר, מיקרוביולוגיה ואימונולוגיה קלינית, סאקלר, אוניברסיטת תל אביב

 

 

 

תחומי מחקר

 

מעבדתי חוקרת את יחסי הגומלין בין מערכת החיסון ובין מלנומה, כמו גם את הביולוגיה של תאי מלנומה. מלנומה היא ממאירות עור קטלנית, הנוטה לשלוח גרורות במהירות ומהווה את גורם התמותה מסרטן השישי בעולם המערבי, כששיעורי המלנומה בישראל הם מהגבוהים בעולם. אנו שמים דגש על זיהוי מנגנונים ביולוגיים מרכזיים ופיתוח של טכנולוגיות טיפוליות ואבחוניות חדשות. מיקום המעבדה בבית החולים מאפשר לנו גישה מידית לחומרים קליניים מחולים, על מנת לבחון את הרלוונטיות של ממצאי המעבדה בעולם האמיתי. 

 

 

 

פרסומים

 

פרסומים (5 שנים אחרונות):

 

 

1. Besser MJ, Schallmach E, Oved K, Treves A, Markel G, Reiter Y, Schachter J. Modifying IL-2 Concentrations during Culture Improves Function of T Cells for Adoptive Immunotherapy. Cytotherapy. 2009 Jan 16:1-12. [Epub ahead of print]

 

2. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Treves AJ, Freidman E, Dotan Z, Keisari Y, Ramon J and Schachter J. Preclinical evaluation of Tumor Infiltrating Lymphocytes (TIL) adoptive transfer in Renal Cell Carcinoma patients. Anticancer Research.

2009. 29:145-154.

 

3. Eisenkraft A, Krivoy A, Vidan A, Robenshtok E, Hourvitz A, Dushnitsky T and Markel G. Phase I study of a topical skin protectant against chemical warfare agents. 2009. Mil Med. 174: 47-52.

 

4. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi E, Zabari N, Shalmon-Zifroni B, Hardan I, Catane R, Segal E, Markel G, Apter S, Kutshuk I, Nagler A and Schachter J. A phase II study using short term cultured or selected anti-tumor autologous lymphocytes following a non-myeloablative lympho depleting chemotherapy regimen in metastatic melanoma. 2009. J Immunotherapy. Apr 1. [Epub ahead of print].

 

5. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Orenstein A, Nagler A and Schachter J. Matching of natural killer lysis receptors (NKLR) with NKLR-ligands as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. 2009. PLoS ONE. 4(5):e5597. Epub 2009 May 19.

 

6. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunology Immunotherapy. Epub 2009 July 25.

 

7. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010. 16:2646-55.

 

8. Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, Shafferman A, Velan B. The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One. 2010 Jun 18;5(6):e11176

 

9. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, Markel G, Shapira-Frommer R, Schachter J, Besser MJ. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011. 34:212-20.

 

10. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One. 2011. 6:e18936.

 

11. Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G*, Eyal E*. Mutagen-specific mutation signature determines global microRNA binding. PLoS One. 2011;6(11):e27400.

 

12. Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G*, Amer R*. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci. 2011. 52:9368-72

 

13. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M*, Michal L*. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clin Dev Immunol. 2012;2012:290536.

 

14. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther. 2012. 11:1300-10.

 

15. Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother. 2012 61:1833-47.

 

16. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ. Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med. 2012. 3:898-902.

 

17. Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One. 2013;8(2):e57160.

 

18. Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg R, Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One. 2013;8(3):e57922.

 

19. Hochberg M, Gilead L, Markel G, Nemlich Y, Feiler Y, Enk CD, Denichenko P, Karni R, Ingber A. Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes. Arch Dermatol Res. 2013. 305:519-28.

 

20. Burazor I, Imazio M, Markel G, Adler Y. Malignant pericardial effusion. Cardiology. 2013. 124:224-32.

 

21. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013. 19:4792-800.

 

22. Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013. 123:2703-18.

 

23. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013 Sep;18(6):502-8

 

 

 

 

מאמרי סקירה:

 

1. Shrot S, Markel G, Dushnitsky T and Krivoy A. The possible use of oximes as antidotal therapy in organophosphate-induced brain damage.. Neurotoxicology. 2009. 30:167-73.

 

2. Imazio M, Spodick DH, Brucato A, Trinchero R, Markel G, Adler Y. Diagnostic issues in the clinical management of pericarditis. Int J Clin Pract. 2010. 64(10):1384-92.

 

3.Imazio M, Mayosi BM, Brucato A, Markel G, Trinchero R, Spodick DH, Adler Y. Triage and management of pericardial effusion. J Cardiovasc Med (Hagerstown). 2010. 11(12):928-35.

 

4. Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, Adler Y. Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome. Am J Cardiol. 2011. 108(4):575-9.

 

5. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target. Curr Top Med Chem. 2012;12(1):3-10.

 

6. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. 2012;12:818214.

 

7. Markel G, Imazio M, Brucato A, Adler Y. Prevention of recurrent pericarditis with colchicine in 2012. Clin Cardiol. 2013 Mar;36(3):125-8.

 

8. Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Adoptive T-cell transfer in melanoma. Immunotherapy. 2013. 5(1):79-90.

 

9. Greenberg E, Nemlich Y, Schachter J, Markel G. microRNAs in cancer: lessons from melanoma. Current Pharmaceutical Design, 2014 ACCEPTED FOR PUBLICATION.

 

 

 

אוניברסיטת תל-אביב, ת.ד. 39040, תל-אביב 6997801
UI/UX Basch_Interactive